Browsing by Author "Garrido S., Marcelo"
Now showing 1 - 14 of 14
Results Per Page
Sort Options
- ItemA case-control study of a combination of single nucleotide polymorphisms and clinical parameters to predict clinically relevant toxicity associated with fluoropyrimidine and platinum-based chemotherapy in gastric cancer(2021) Cordova-Delgado, Miguel; Bravo Castillo, María Loreto; Cumsille, Elisa; Hill Machado, Charlotte Nicole; Pinto, Mauricio P.; Miquel P., Juan Francisco; Rodríguez-Fernández, María; Corvalán R., Alejandro; Garrido S., Marcelo; Owen, Gareth IvorBackground: Fluoropyrimidine plus platinum chemotherapy remains the standard first line treatment for gastric cancer (GC). Guidelines exist for the clinical interpretation of four DPYD genotypes related to severe fluoropyrimidine toxicity within European populations. However, the frequency of these single nucleotide polymorphisms (SNPs) in the Latin American population is low (< 0.7%). No guidelines have been development for platinum. Herein, we present association between clinical factors and common SNPs in the development of grade 3–4 toxicity. Methods: Retrospectively, 224 clinical records of GC patient were screened, of which 93 patients were incorporated into the study. Eleven SNPs with minor allelic frequency above 5% in GSTP1, ERCC2, ERCC1, TP53, UMPS, SHMT1, MTHFR, ABCC2 and DPYD were assessed. Association between patient clinical characteristics and toxicity was estimated using logistic regression models and classification algorithms. Results; Reported grade ≤ 2 and 3–4 toxicities were 64.6% (61/93) and 34.4% (32/93) respectively. Selected DPYD SNPs were associated with higher toxicity (rs1801265; OR = 4.20; 95% CI = 1.70–10.95, p = 0.002), while others displayed a trend towards lower toxicity (rs1801159; OR = 0.45; 95% CI = 0.19–1.08; p = 0.071). Combination of paired SNPs demonstrated significant associations in DPYD (rs1801265), UMPS (rs1801019), ABCC2 (rs717620) and SHMT1 (rs1979277). Using multivariate logistic regression that combined age, sex, peri-operative chemotherapy, 5-FU regimen, the binary combination of the SNPs DPYD (rs1801265) + ABCC2 (rs717620), and DPYD (rs1801159) displayed the best predictive performance. A nomogram was constructed to assess the risk of developing overall toxicity. Conclusion: Pending further validation, this model could predict chemotherapy associated toxicity and improve GC patient quality of life.
- ItemA Molecular Stratification of Chilean Gastric Cancer Patients with Potential Clinical Applicability(2020) Pinto Paganini, Mauricio Arturo; Bravo Castillo, Maria Loreto; Sánchez Rojel, César Giovanni; Acevedo, Francisco; Mondaca Contreras, Sebastián Patricio; Ibañez, Carolina; Galindo A., Héctor; Madrid Arenas, Jorge; Nervi Nattero, Bruno; Peña Durán, José Esteban; Torres Montes, Paula Javiera; Owen, Gareth Ivor; Corvalán R., Alejandro; Garrido S., Marcelo; Córdova Delgado, M.; Retamal, I. N.; Muñoz Medel, M.; Durán, D.; Villanueva, F.; Koch, E.; Armisen, R.
- ItemChallenges in first line chemotherapy and targeted therapy in advanced gastric cancer(2014) Garrido S., Marcelo; Fonseca, P.; Vieitez, J.; Frunza, M.; Lacave, A.
- ItemEfficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer : the KEYNOTE-062 phase 3 randomized clinical trial(2020) Shitara, K.; Van Cutsem, E.; Bang, Y. J.; Fuchs, C.; Wyrwicz, L.; Lee, K.W.; Kudaba, I.; Garrido S., Marcelo; Chung, H. C.; Lee, J.; Castro, H. R.; Mansoor, W.; Braghiroli, M. I.; Karaseva, N.; Caglevic, C.; Villanueva, L.; Goekkurt, E.; Satake, H.; Enzinger, P.; Alsina, M.; Benson, A.; Chao, J.; Ko, A. H.; Wainberg, Z. A.; Kher, U.; Shah, S.; Kang, S. P.; Tabernero, J.
- ItemHealth-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma : KEYNOTE-240(2021) Ryoo, B. Y.; Merle, P.; Kulkarni, A. S.; Cheng, A. L.; Bouattour, M.; Lim, H. Y.; Breder, V.; Edeline, J.; Chao, Y.; Garrido S., Marcelo; Ogasawara, S.; Yau, T.; Chan, S. L.; Daniele, B.; Norquist, J. M.; Chen, E.; Siegel, A. B.; Zhu, A. X.; Finn, R. S.; Kudo, M.
- ItemMultistate Models: Accurate and Dynamic Methods to Improve Predictions of Thrombotic Risk in Patients with Cancer(2019) Carmona-Bayonas, A.; Jimenez-Fonseca, P.; Garrido S., Marcelo; Custodio, A.; Hernandez, R.; Lacalle, A.; Cano, J.M.; Aguado, G.; De Castro, E.M.; Mancenido, F.A.; Macias, I.; Visa, L.; Richard, M.M.; Mangas, M.; Canovas, M.S.; Longo, F.; Rey, L.I.; Lago, N.M.; Carnicero, A.M.; Sanchez, A.; Azkarate, A.; Limon, M.L.; Perez, C.H.; Ramchandani, A.; Pimentel, P.; Cerda, P.; Serrano, R.; Gil-Negrete, A.; Marin, M.; Hurtado, A.; Bayona, R.S.; Gallego, J.
- ItemPembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma : results from the phase II nonrandomized KEYNOTE-059 study(2019) Bang, Y.J.; Kang, Y.K.; Catenacci, D.V.; Muro, K.; Fuchs, C.S.; Geva, R.; Hara, H.; Golan, T.; Garrido S., Marcelo; Jalal, S.I.; Borg, C.; Doi, T.; Yoon, H.H.; Savage, M.J.; Wang, J.; Dalal, R.P.; Shah, S.; Wainberg, Z.A.; Chung, H.C.
- ItemPembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010) : a randomised controlled trial(2016) Herbst, Roy S.; Baas, Paul; Kim, Dong-Wan; Felip, Enriqueta; Pérez-Gracia, José L.; Han, Ji-YouN.; Molina, Julián; Kim, Joo-Hang; Dubos Arvis, Catherine; Garrido S., Marcelo
- ItemPerformance of the clinical index of stable febrile neutropenia (CISNE) in different types of infections and tumors(2017) Garrido S., Marcelo; Carmona Bayonas, Alberto; Jiménez Fonseca, P.; Virizuela Echaburu, J.A.; Antonio, Maite; Font Puig, Carme; Biosca Gomez de Tejada, Mercedes; Ramchandani Vaswani, Avi; Martinez Garcia, Jerónimo; Hernando Cubero, Jorge; Espinosa Arranz, Javier; Martínez de Castro, Eva; Ghanem, I.; Beato, C.; Blasco, A.; Mondéjar, R.
- ItemRuxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy : JANUS 1 and 2 randomized phase III studies(2018) Hurwitz, Herbert; Van Cutsem, Eric; Bendell, Johanna; Hidalgo, Manuel; Chung-Pin Li; Garrido S., Marcelo; Macarulla, Teresa; Sahai, Vaibhav; Sama, Ashwin; Greeno, Edward
- ItemSafety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: Phase 2 clinical KEYNOTE-059 trial(2018) Fuchs, C. S.; Doi, T.; Jang, R. W.; Muro, K.; Satoh, T.; Machado, M.; Sun, W.; Jalal, S. I.; Shah, M. A.; Garrido S., Marcelo; Metges, J. P.
- ItemSecond-line treatment in advanced gastric cancer : Data from the Spanish AGAMENON registry(2020) Sanchis, A. C.; Gallego, J.; Hernandez, R.; Arrazubi, V.; Custodio, A.; Cano, J. M.; Aguado, G.; Macias, I.; Lopez, C.; Garrido S., Marcelo; Lopez, F.; Visa, L.; Lago, N. M.; Montes, A. F.; Limon, M. L.; Azkarate, A.; Pimentel, P.; Reguera, P.; Ramchandani, A.; Cacho, J. D.; Carnicero, A. M.; Granja, M.; Richard, M. M.; Perez, C. H.; Hurtado, A.; Serra, O.; Buxo, E.; Tocino, R. V.; Jimenez-Fonseca, P.; Carmona-Bayonas, A.
- ItemSurgery for metastases for esophageal-gastric cancer in the real world: Data from the AGAMENON national registry(2018) Carmona Bayonas, Alberto; Jiménez Fonseca, Paula; Echavarría, Isabel; Sánchez Cánovas, Manuel; Aguado, Gema; Gallego, Javier; Custodio, Ana; Raquel Hernández, Raquel; Viudez, Antonio; Garrido S., Marcelo; et al.
- ItemThe reprimo-like gene is an epigenetic-mediated tumor suppressor and a candidate biomarker for the non-invasive detection of gastric cancer(2020) Alarcón Alarcón, María Alejandra; Olivares, W.; Córdova Delgado, M.; Wichmann Pérez, Ignacio Alberto; Amigo, Julio; Norero Muñoz, Enrique; Riquelme Pérez, Arnoldo; Garrido S., Marcelo; Owen, Gareth Ivor; Corvalán R., Alejandro; Muñoz-Medel, M.; Mayo, T. de; Carrasco-Aviño, G.; Landeros, N.; Villarroel Espíndola, F.